Drug Trial Radar · NCT07467447
Effect of Retatrutide Versus Placebo in Participants Who Have Obesity or Are Overweight
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Feb 15, 2026
Primary completion
Mar 14, 2027
Study completion Feb 17, 2028
Sponsor
- Lead sponsor
- Hudson BiotechIndustry
- Sponsor type
- Industry
- First posted
- Mar 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 2, multicenter, randomized, double-blind, placebo-controlled study evaluating once-weekly subcutaneous retatrutide (LY3437943) at multiple maintenance dose levels versus placebo in adults with obesity or overweight with weight-related comorbidities (without type 2 diabetes), alongside standardized diet and physical activity counseling.
Conditions
- Obesity
Interventions
Retatrutide (LY3437943)Drug
subcutaneous injection, once weekly (dose per assigned arm).
PlaceboDrug
subcutaneous injection, once weekly (schedule matched to an active arm).
Standardized diet and physical activity counseling throughout the study.Behavioral
Standardized diet and physical activity counseling throughout the study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean percent change in body weight from randomization/baseline to Week 24.Time frame: 24 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University Shenzhen Hospital
Shenzhen, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.